<Protocol id="CDR0000347393" LegacyPDQID=""><ProtocolIDs><PrimaryID><IDString>COG-ADVL0215</IDString></PrimaryID><OtherID><IDType>ClinicalTrials.gov ID</IDType><IDString>NCT00075634</IDString></OtherID></ProtocolIDs><FundingInfo><NIHGrantContract><NIHGrantContractType>U01</NIHGrantContractType><GrantContractNo>U01-CA97452</GrantContractNo></NIHGrantContract></FundingInfo><ProtocolSponsor>NCI</ProtocolSponsor><ProtocolTitle Audience="Professional">Phase I Study of Decitabine, Doxorubicin,  and Cyclophosphamide in Children With Relapsed or Refractory Solid Tumors or Neuroblastoma</ProtocolTitle><ProtocolTitle Audience="Patient">Decitabine, Doxorubicin,  and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma</ProtocolTitle><ProtocolAbstract><Professional><Objectives><OrderedList Style="URoman" id="_6"><ListTitle>Primary</ListTitle><ListItem>Determine the maximum tolerated dose of decitabine in combination with doxorubicin and cyclophosphamide in children with relapsed or refractory solid tumors or neuroblastoma.</ListItem><ListItem>Determine the toxic effects of this regimen in these patients.</ListItem><ListItem>Determine whether decitabine induces tumor caspase-8 demethylation and expression in these patients.</ListItem></OrderedList><OrderedList Style="URoman" id="_7"><ListTitle>Secondary</ListTitle><ListItem>Determine the pharmacokinetics of low-dose decitabine in these patients.</ListItem><ListItem>Determine the biological and clinical response in patients treated with this regimen.</ListItem><ListItem>Compare patterns of peripheral blood gene expression, using gene expression profiling, in patients before and after treatment with decitabine.</ListItem></OrderedList></Objectives><Outline><Para id="_8">This is a multicenter, dose-escalation study of decitabine.</Para><ItemizedList Compact="No" Style="bullet" id="_9"><ListItem><Emphasis><Strong>Part A (solid tumor patients):</Strong></Emphasis> Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.<Para id="_10">Cohorts of 3-6 patients receive escalating doses of decitabine until the 
maximum tolerated dose (MTD) is determined.  The MTD is defined as the dose 
preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. 
</Para><Para id="_44"><Note>*For patients &gt; 45 kg</Note></Para></ListItem><ListItem><Emphasis><Strong>Part B (neuroblastoma patients):</Strong></Emphasis> Once the MTD is determined for part A, patients are treated as in part A at the MTD .</ListItem></ItemizedList><Para id="_11">Patients are followed at 30 days.</Para></Outline><EntryCriteria><DiseaseCharacteristics><ItemizedList Compact="No" Style="bullet" id="_12"><ListItem>Histologically confirmed diagnosis of either of the following:<ItemizedList Style="dash" id="_13"><ListItem>Solid tumor (part A)<ItemizedList Style="bullet" id="_14"><ListItem>No lymphoma</ListItem></ItemizedList></ListItem><ListItem>Neuroblastoma (part B)<ItemizedList Style="bullet" id="_15"><ListItem>Original diagnosis may be based on elevated  urine vanillylmandelic acid (VMA) and homovanillic acid (HVA) and bone marrow examination</ListItem><ListItem>Accessible disease by bone marrow aspirate or tumor biopsy<ItemizedList Style="dash" id="_16"><ListItem>No laparotomy, thoracotomy, endoscopy, or craniotomy for biopsy</ListItem></ItemizedList></ListItem></ItemizedList></ListItem></ItemizedList></ListItem><ListItem>No known curative therapy OR therapy proven to prolong survival with an acceptable quality of life available </ListItem><ListItem>No known brain or spinal cord metastases</ListItem><ListItem>No CNS tumors</ListItem></ItemizedList></DiseaseCharacteristics><PatientCharacteristics><ItemizedList Style="bullet" id="_17"><ListTitle>Age</ListTitle><ListItem>Over 12 months to 21 years</ListItem></ItemizedList><ItemizedList Style="bullet" id="_18"><ListTitle>Performance status</ListTitle><ListItem>Karnofsky 50-100%  (patients 11 to 21 years of age)</ListItem><ListItem>Lansky 50-100% (patients ≤ 10 years of age)</ListItem></ItemizedList><ItemizedList Style="bullet" id="_19"><ListTitle>Life expectancy</ListTitle><ListItem>Not specified</ListItem></ItemizedList><ItemizedList Style="bullet" id="_20"><ListTitle>Hematopoietic</ListTitle><ListItem>Parts A and B without bone marrow infiltration:<ItemizedList Style="dash" id="_21"><ListItem>Absolute neutrophil count ≥  1,000/mm<Superscript>3</Superscript></ListItem><ListItem>Platelet count ≥ 100,000/mm<Superscript>3</Superscript> (transfusion independent)</ListItem></ItemizedList></ListItem><ListItem>Part B with bone marrow infiltration (i.e., tumor metastatic to bone marrow with granulocytopenia, anemia, and/or thrombocytopenia):<ItemizedList Style="dash" id="_22"><ListItem>Absolute neutrophil count ≥ 750/mm<Superscript>3</Superscript></ListItem><ListItem>Platelet count ≥ 50,000/mm<Superscript>3</Superscript> (transfusion independent)</ListItem></ItemizedList></ListItem><ListItem>Hemoglobin ≥ 8.0 g/dL (transfusion allowed)</ListItem><ListItem>No sickle cell anemia</ListItem></ItemizedList><ItemizedList Style="bullet" id="_23"><ListTitle>Hepatic</ListTitle><ListItem>Bilirubin ≤ 1.5 mg/dL</ListItem><ListItem>ALT ≤ 5 times upper limit of normal</ListItem><ListItem>No significant hepatic dysfunction that would compromise the tolerability of decitabine or interfere with study procedures or results</ListItem></ItemizedList><ItemizedList Style="bullet" id="_24"><ListTitle>Renal</ListTitle><ListItem>Creatinine based on age as follows:<ItemizedList Style="dash" id="_25"><ListItem>≤ 0.8 mg/dL (5 years of age and under)</ListItem><ListItem>≤ 1.0 mg/dL (6 to 10 years of age)</ListItem><ListItem>≤ 1.2 mg/dL (11 to 15 years of age)</ListItem><ListItem>≤ 1.5 mg/dL (16 to 21 years of age)</ListItem></ItemizedList><Para id="_26">OR</Para></ListItem><ListItem>Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min</ListItem><ListItem>No significant renal dysfunction that would compromise the tolerability of decitabine or interfere with study procedures or results</ListItem></ItemizedList><ItemizedList Style="bullet" id="_27"><ListTitle>Cardiovascular</ListTitle><ListItem>Shortening fraction ≥ 28% by echocardiogram<Para id="_28">OR</Para></ListItem><ListItem>Ejection fraction of ≥ 45% by MUGA</ListItem></ItemizedList><ItemizedList Style="bullet" id="_29"><ListTitle>Pulmonary</ListTitle><ListItem>No significant pulmonary dysfunction that would compromise the tolerability of decitabine or interfere with study procedures or results</ListItem></ItemizedList><ItemizedList Style="bullet" id="_30"><ListTitle>Other</ListTitle><ListItem>Not pregnant or nursing</ListItem><ListItem>Negative pregnancy test</ListItem><ListItem>Fertile patients must use effective contraception</ListItem><ListItem>No prior allergic reaction attributed to compounds of similar chemical or biological composition to agents used in this study</ListItem><ListItem>No uncontrolled serious infection</ListItem><ListItem>No significant end-organ dysfunction that would compromise the tolerability of decitabine or interfere with study procedures or results</ListItem></ItemizedList></PatientCharacteristics><PriorConcurrentTherapy><ItemizedList Style="bullet" id="_31"><ListTitle>Biologic therapy</ListTitle><ListItem>Recovered from prior immunotherapy</ListItem><ListItem>At least 7 days since prior biologic therapy</ListItem><ListItem>More than 1 week since prior growth factor therapy (2 weeks for pegfilgrastim)</ListItem><ListItem>More than 2 weeks since prior epoetin alfa</ListItem><ListItem>At least 6 months since prior autologous stem cell transplantation</ListItem><ListItem>At least 6 months since prior allogeneic bone marrow transplantation<ItemizedList Style="dash" id="_32"><ListItem>Patients must have full organ recovery and no evidence of graft-versus-host disease</ListItem></ItemizedList></ListItem><ListItem>No concurrent immunomodulating agents</ListItem><ListItem>No concurrent immunotherapy</ListItem><ListItem>No concurrent biologic therapy</ListItem><ListItem>No concurrent epoetin alfa</ListItem></ItemizedList><ItemizedList Style="bullet" id="_33"><ListTitle>Chemotherapy</ListTitle><ListItem>Recovered from prior chemotherapy</ListItem><ListItem>More than 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)</ListItem><ListItem>Prior total lifetime cumulative anthracycline dose ≤ 450 mg/m<Superscript>2</Superscript> of doxorubicin or equivalent</ListItem><ListItem>No other concurrent chemotherapy</ListItem><ListItem>No concurrent hydroxyurea</ListItem></ItemizedList><ItemizedList Style="bullet" id="_34"><ListTitle>Endocrine therapy</ListTitle><ListItem>Not specified</ListItem></ItemizedList><ItemizedList Style="bullet" id="_35"><ListTitle>Radiotherapy</ListTitle><ListItem>Recovered from prior radiotherapy</ListItem><ListItem>More than 2 weeks since prior local palliative small port radiotherapy</ListItem><ListItem>More than 6 months since prior substantial bone marrow irradiation (e.g., cranio-spinal irradiation, total body irradiation, or hemi-pelvic irradiation)</ListItem><ListItem>No concurrent radiotherapy</ListItem></ItemizedList><ItemizedList Style="bullet" id="_36"><ListTitle>Surgery</ListTitle><ListItem>Not specified</ListItem></ItemizedList><ItemizedList Style="bullet" id="_37"><ListTitle>Other</ListTitle><ListItem>No other concurrent anticancer therapy</ListItem><ListItem>No other concurrent investigational agents</ListItem><ListItem>Concurrent oral iron supplementation for patients with a known iron deficiency or a microcytic hypochromic anemia allowed</ListItem></ItemizedList></PriorConcurrentTherapy></EntryCriteria><ProjectedAccrual><Para id="_38">A total of 15-21 patients will be accrued for this study within 1-2 years.</Para></ProjectedAccrual><ProfessionalDisclaimer><Para id="_ProtHPDisclaimer_5">The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer.  Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test.  The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment.  A responsible investigator associated with this clinical trial should be consulted before using this protocol.</Para></ProfessionalDisclaimer></Professional><Patient><Rationale><Para id="_39"><GlossaryTermRef href="CDR0000348921">Drugs</GlossaryTermRef> used in <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef>, such as <GlossaryTermRef href="CDR0000045208">decitabine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045140">doxorubicin</GlossaryTermRef>,   and <GlossaryTermRef href="CDR0000045253">cyclophosphamide</GlossaryTermRef>,  work in  different ways to stop <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef> from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.  </Para></Rationale><Purpose><Para id="_40">This <GlossaryTermRef href="CDR0000045830">phase I trial</GlossaryTermRef> is studying the <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef> and best <GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> of decitabine when given together with doxorubicin and cyclophosphamide in treating children with <GlossaryTermRef href="CDR0000045866">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045863">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000045301">solid tumors</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045418">neuroblastoma</GlossaryTermRef>.</Para></Purpose><EligibilityText><Para id="_43"><GlossaryTermRef href="CDR0000346518">Eligibility criteria</GlossaryTermRef> include the following:</Para><ItemizedList Style="bullet" id="_41"><ListItem>13 months-21 years old</ListItem><ListItem>No <GlossaryTermRef href="CDR0000045368">lymphoma</GlossaryTermRef></ListItem><ListItem>No <GlossaryTermRef href="CDR0000045314">brain metastases</GlossaryTermRef> or <GlossaryTermRef href="CDR0000340937">spinal cord</GlossaryTermRef><GlossaryTermRef href="CDR0000046710">metastases</GlossaryTermRef></ListItem><ListItem>No <GlossaryTermRef href="CDR0000045645">CNS tumors</GlossaryTermRef></ListItem><ListItem>At least 1 week since <GlossaryTermRef href="CDR0000045617">biological therapy</GlossaryTermRef></ListItem><ListItem>At least 6 months since <GlossaryTermRef href="CDR0000046695">stem cell</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045263">bone marrow transplantation</GlossaryTermRef></ListItem><ListItem>More than 2 weeks since chemotherapy</ListItem><ListItem>More than 6 months since <GlossaryTermRef href="CDR0000045930">total-body irradiation</GlossaryTermRef> or <GlossaryTermRef href="CDR0000044971">radiation therapy</GlossaryTermRef> to the brain and <GlossaryTermRef href="CDR0000415914">spine</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046246">pelvis</GlossaryTermRef></ListItem></ItemizedList><Para id="_EligibilityDisclaimer_3">Final eligibility for a clinical trial is determined by the health professionals conducting the trial. For more details about the eligibility requirements for this trial and the treatment or intervention, refer to the <ExternalRef xref="http://www.cancer.gov/clinicaltrials/COG-ADVL0215">Health Professional version</ExternalRef> of the trial summary.</Para></EligibilityText><TreatmentIntervention><Para id="_42">Patients will receive a 1-hour <GlossaryTermRef href="CDR0000045738">infusion</GlossaryTermRef> of decitabine on days 1-7. They will receive an infusion of doxorubicin and a 1-hour infusion of cyclophosphamide on day 8. Patients will receive <GlossaryTermRef href="CDR0000044678">injections</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045332">filgrastim</GlossaryTermRef> beginning on day 9 and continuing until <GlossaryTermRef href="CDR0000044648">blood counts</GlossaryTermRef> return to normal OR an injection of <GlossaryTermRef href="CDR0000316080">pegfilgrastim</GlossaryTermRef> once on day 8 or 9. Treatment may be repeated every 4 weeks for up to 12 courses. Patients will be evaluated at 1 month.</Para></TreatmentIntervention><PatientDisclaimer><Para id="_ProtPatientDisclaimer_4"><Strong>Important:</Strong></Para><Para id="_ProtPatientDisclaimer_2">If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on

<ExternalRef xref="http://cancer.gov/clinicaltrials">NCI's Web site</ExternalRef>.</Para></PatientDisclaimer></Patient></ProtocolAbstract><ProtocolDetail><StudyType>Clinical trial</StudyType><StudyCategory><StudyCategoryName>Treatment</StudyCategoryName><Intervention><InterventionType ref="CDR0000039455">chemotherapy</InterventionType><InterventionNameLink ref="CDR0000039299">decitabine</InterventionNameLink><InterventionNameLink ref="CDR0000038860">doxorubicin hydrochloride</InterventionNameLink><InterventionNameLink ref="CDR0000039748">cyclophosphamide</InterventionNameLink></Intervention><Intervention><InterventionType ref="CDR0000040692">colony-stimulating factor therapy</InterventionType><InterventionTypeParent ref="CDR0000041550">cytokine therapy</InterventionTypeParent><InterventionTypeParent ref="CDR0000040815">biological response modifier therapy</InterventionTypeParent><InterventionNameLink ref="CDR0000041057">filgrastim</InterventionNameLink><InterventionNameLink ref="CDR0000037807">pegfilgrastim</InterventionNameLink></Intervention><Intervention><InterventionType ref="CDR0000038581">combination therapy</InterventionType><InterventionNameLink ref="CDR0000349494">cyclophosphamide/decitabine/doxorubicin</InterventionNameLink></Intervention></StudyCategory></ProtocolDetail><Eligibility><HealthyVolunteers>No</HealthyVolunteers><LowAge>1</LowAge><HighAge>21</HighAge><AgeText>Over 12 months to 21 years</AgeText><Diagnosis><SpecificDiagnosis ref="CDR0000038972">unspecified childhood solid tumor, protocol specific</SpecificDiagnosis><DiagnosisParent ref="CDR0000043724">childhood cancer</DiagnosisParent><DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent><DiagnosisParent ref="CDR0000039053">childhood solid tumor</DiagnosisParent><DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent></Diagnosis><Diagnosis><SpecificDiagnosis ref="CDR0000043713">recurrent neuroblastoma</SpecificDiagnosis><DiagnosisParent ref="CDR0000042067">neuroblastoma</DiagnosisParent><DiagnosisParent ref="CDR0000043724">childhood cancer</DiagnosisParent><DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent><DiagnosisParent ref="CDR0000038966">central nervous system cancer</DiagnosisParent><DiagnosisParent ref="CDR0000043666">body system/site cancer</DiagnosisParent><DiagnosisParent ref="CDR0000039053">childhood solid tumor</DiagnosisParent><DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent></Diagnosis></Eligibility><PublishedResults>George RE, Medeiros-Nancarrow C, Adamson PC, et al.: A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors - a Children's Oncology Group study. [Abstract] J Clin Oncol  23 (Suppl 16): A-8530, 807s,  2005</PublishedResults><ProtocolPhase>Phase I</ProtocolPhase><ProtocolSpecialCategory>NIH Clinical Center trial</ProtocolSpecialCategory><ProtocolAdminInfo><CurrentProtocolStatus>Active</CurrentProtocolStatus><ProtocolLeadOrg><LeadOrgName ref="CDR0000033155">Children's Oncology Group</LeadOrgName><LeadOrgRole>Primary</LeadOrgRole><LeadOrgProtocolID>COG-ADVL0215</LeadOrgProtocolID><LeadOrgProtocolStatus><StatusName>Active</StatusName><StatusDate>2005-02-22</StatusDate></LeadOrgProtocolStatus><LeadOrgPersonnel><ProtPerson ref="CDR0000347388#_1"><PersonNameInformation><GivenName>Rani</GivenName><SurName>George</SurName><ProfessionalSuffix>MD, PhD</ProfessionalSuffix></PersonNameInformation><PersonRole>Protocol chair</PersonRole><Contact><ContactDetail><OrganizationName>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</OrganizationName><PostalAddress><Street>Department of Pediatric Oncology</Street><Street>Dana 322</Street><Street>44 Binney Street</Street><City>Boston</City><PoliticalSubUnitName ref="CDR0000043878">Massachusetts</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCode_ZIP>02115</PostalCode_ZIP><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>617-632-5281</Phone><TollFreePhone>800-790-4500</TollFreePhone></ContactDetail></Contact></ProtPerson><ProtPerson ref="CDR0000012147#F1"><PersonNameInformation><GivenName>Lisa</GivenName><SurName>Diller</SurName><ProfessionalSuffix>MD</ProfessionalSuffix></PersonNameInformation><PersonRole>Protocol co-chair</PersonRole><Contact><ContactDetail><OrganizationName>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</OrganizationName><PostalAddress><Street>44 Binney Street</Street><City>Boston</City><PoliticalSubUnitName ref="CDR0000043878">Massachusetts</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCode_ZIP>02115</PostalCode_ZIP><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>617-632-5642</Phone><TollFreePhone>800-790-4500</TollFreePhone><Email>lisa_diller@dfci.harvard.edu</Email></ContactDetail></Contact></ProtPerson></LeadOrgPersonnel></ProtocolLeadOrg><ProtocolSites><ProtocolSite ref="CDR0000032339" sitetype="Organization"><SiteName>Cancer Institute at Oregon Health and Science University</SiteName><ProtPerson><PersonRole>Clinical Trials Office</PersonRole><Contact><ContactDetail><PostalAddress><City>Portland</City><PoliticalSubUnitName ref="CDR0000043894">Oregon</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>503-494-1080</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000030037" sitetype="Organization"><SiteName>Children's Hospital and Regional Medical Center - Seattle</SiteName><ProtPerson><PersonNameInformation><GivenName>Douglas</GivenName><MiddleInitial /><SurName>Hawkins</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Seattle</City><PoliticalSubUnitName ref="CDR0000043904">Washington</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>206987-3096</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029515" sitetype="Organization"><SiteName>Children's Hospital of Philadelphia</SiteName><ProtPerson><PersonNameInformation><GivenName>Richard</GivenName><MiddleInitial /><SurName>Womer</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Philadelphia</City><PoliticalSubUnitName ref="CDR0000043895">Pennsylvania</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>215590-2229</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029152" sitetype="Organization"><SiteName>Children's Hospital of Pittsburgh</SiteName><ProtPerson><PersonNameInformation><GivenName>A.</GivenName><MiddleInitial>Kim</MiddleInitial><SurName>Ritchey</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Pittsburgh</City><PoliticalSubUnitName ref="CDR0000043895">Pennsylvania</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>412692-5947</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029421" sitetype="Organization"><SiteName>Children's National Medical Center</SiteName><ProtPerson><PersonNameInformation><GivenName>Nita</GivenName><MiddleInitial /><SurName>Seibel</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Washington</City><PoliticalSubUnitName ref="CDR0000043865">District of Columbia</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>202884-2144</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000037012" sitetype="Organization"><SiteName>Cincinnati Children's Hospital Medical Center</SiteName><ProtPerson><PersonNameInformation><GivenName>John</GivenName><MiddleInitial /><SurName>Perentesis</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Cincinnati</City><PoliticalSubUnitName ref="CDR0000043892">Ohio</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>513636-4266</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000031539" sitetype="Organization"><SiteName>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</SiteName><ProtPerson><PersonNameInformation><GivenName>Holcombe</GivenName><MiddleInitial /><SurName>Grier</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Boston</City><PoliticalSubUnitName ref="CDR0000043878">Massachusetts</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>617632-3971</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000031732" sitetype="Organization"><SiteName>Fairview University Medical Center - University Campus</SiteName><ProtPerson><PersonNameInformation><GivenName>Joseph</GivenName><MiddleInitial /><SurName>Neglia</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Minneapolis</City><PoliticalSubUnitName ref="CDR0000043880">Minnesota</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>612626-2778</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029082" sitetype="Organization"><SiteName>Herbert Irving Comprehensive Cancer Center at Columbia University</SiteName><ProtPerson><PersonNameInformation><GivenName>Linda</GivenName><MiddleInitial /><SurName>Granowetter</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>New York</City><PoliticalSubUnitName ref="CDR0000043889">New York</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>212305-9770x8652</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000036296" sitetype="Organization"><SiteName>Hopital Sainte Justine</SiteName><ProtPerson><PersonNameInformation><GivenName>Albert</GivenName><MiddleInitial /><SurName>Moghrabi</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Montreal</City><PoliticalSubUnitName ref="CDR0000043919">Quebec</PoliticalSubUnitName><CountryName ref="CDR0000043766">Canada</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>514345-4969</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029315" sitetype="Organization"><SiteName>Hospital for Sick Children</SiteName><ProtPerson><PersonNameInformation><GivenName>Alberto</GivenName><MiddleInitial /><SurName>Pappo</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Toronto</City><PoliticalSubUnitName ref="CDR0000043910">Ontario</PoliticalSubUnitName><CountryName ref="CDR0000043766">Canada</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>416813-6194</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000032354" sitetype="Organization"><SiteName>Mayo Clinic Cancer Center</SiteName><ProtPerson><PersonNameInformation><GivenName>Carola</GivenName><MiddleInitial>A.S.</MiddleInitial><SurName>Arndt</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Rochester</City><PoliticalSubUnitName ref="CDR0000043880">Minnesota</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>507284-3442</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000028999" sitetype="Organization"><SiteName>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</SiteName><ProtPerson><PersonNameInformation><GivenName>Naomi</GivenName><MiddleInitial /><SurName>Winick</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Dallas</City><PoliticalSubUnitName ref="CDR0000043900">Texas</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>214456-2382</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000035252" sitetype="Organization"><SiteName>St. Jude Children's Research Hospital</SiteName><ProtPerson><PersonNameInformation><GivenName>Wayne</GivenName><MiddleInitial>Lee</MiddleInitial><SurName>Furman</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Memphis</City><PoliticalSubUnitName ref="CDR0000043899">Tennessee</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>901495-2403</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000034940" sitetype="Organization"><SiteName>Stanford Cancer Center at Stanford University Medical Center</SiteName><ProtPerson><PersonNameInformation><GivenName>Neyssa</GivenName><MiddleInitial /><SurName>Marina</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Palo Alto</City><PoliticalSubUnitName ref="CDR0000043861">California</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>650723-5535</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000029179" sitetype="Organization"><SiteName>SUNY Upstate Medical University Hospital</SiteName><ProtPerson><PersonNameInformation><GivenName>Ronald</GivenName><MiddleInitial /><SurName>Dubowy</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Syracuse</City><PoliticalSubUnitName ref="CDR0000043889">New York</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>315464-5294</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite><ProtocolSite ref="CDR0000028379" sitetype="Organization"><SiteName>University of Mississippi Medical Center</SiteName><ProtPerson><PersonNameInformation><GivenName>Gail</GivenName><MiddleInitial>C.</MiddleInitial><SurName>Megason</SurName></PersonNameInformation><PersonRole>Principal investigator</PersonRole><Contact><ContactDetail><PostalAddress><City>Jackson</City><PoliticalSubUnitName ref="CDR0000043881">Mississippi</PoliticalSubUnitName><CountryName ref="CDR0000043753">U.S.A.</CountryName><PostalCodePosition>after PoliticalSubUnit_State</PostalCodePosition></PostalAddress><Phone>601984-5220</Phone></ContactDetail></Contact></ProtPerson></ProtocolSite></ProtocolSites></ProtocolAdminInfo><DateFirstPublished>2003-12-23</DateFirstPublished><DateLastModified>2005-12-28</DateLastModified></Protocol>